-
Article
Nerve-sparing radical prostatectomy using the neurovascular structure-adjacent frozen-section examination (NeuroSAFE): results after 20 years of experience
To evaluate the long-term oncological outcomes and functional results of the neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during nerve-sparing (NS) radical prostatectomy (RP).
-
Article
Open AccessSynthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysins
Fascaplysin is a red cytotoxic pigment with anticancer properties isolated from the marine sponge Fascaplysinopsis sp. Recently, structure–activity relationship analysis reported by our group suggested that selec...
-
Article
Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients
It is unknown whether the stage of the primary may influence the survival (OS) of metastatic upper tract urothelial carcinoma (mUTUC) patients treated with nephroureterectomy (NU) and systemic therapy (ST). We...
-
Article
Open AccessIs extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?
-
Article
Robot-assisted vs open retropubic radical prostatectomy: a propensity score-matched comparative analysis based on 15 years and 18,805 patients
To compare oncological, functional, and surgical outcomes of a large cohort of patients who underwent open retropubic radical prostatectomy (ORP) or robot-assisted radical prostatectomy (RARP).
-
Article
Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review
Das Prostatakarzinom ist die häufigste Tumorerkrankung bei Männern. Es sind insbesondere Männer im fortgeschrittenen Alter mit einer erhöhten Prävalenz für das metabolische Syndrom und kardiovaskuläre Erkranku...
-
Article
Systemtherapie des Prostatakarzinoms im hohen Alter
Die meisten Prostatakarzinome (PCa) werden jenseits des 65. Lebensjahrs diagnostiziert. Dennoch ist die Zahl der älteren, gebrechlichen Männer in klinischen Studien zum fortgeschrittenen PCa häufig unterrepräs...
-
Article
Open AccessCorrection: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
-
Article
Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls
It is unknown whether five-year overall survival (OS) differs and to what extent between testicular germ-cell tumor (TGCT) patients and age-matched male population-based controls.
-
Article
Open AccessRegional differences in clear cell metastatic renal cell carcinoma patients across the USA
To test for regional differences in clear cell metastatic renal cell carcinoma (ccmRCC) patients across the USA.
-
Article
Characteristics of incidental prostate cancer in the United States
Data regarding North-American incidental (cT1a/b) prostate cancer (PCa) patients is scarce. To address this, incidental PCa characteristics (age, PSA values at diagnosis, Gleason score [GS]), subsequent treatm...
-
Article
Open AccessImpact of persistent PSA after salvage radical prostatectomy: a multicenter study
Persistent prostatic specific antigen (PSA) represents a poor prognostic factor for recurrence after radical prostatectomy (RP). However, the impact of persistent PSA on oncologic outcomes in patients undergoi...
-
Article
Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities
It is unknown to what extent overall survival (OS) of organ-confined (T2N0M0) urothelial carcinoma of the urinary bladder (UCUB) patients differs from age- and sex-matched population-based controls, especially...
-
Article
Open AccessRace/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables
To test the effect of race/ethnicity on Social Security Administration (SSA) life tables’ life expectancy (LE) predictions in localized prostate cancer (PCa) patients treated with either radical prostatectomy ...
-
Article
Open AccessMRI as a screening tool for prostate cancer: current evidence and future challenges
Prostate cancer (PCa) screening, which relies on prostate-specific antigen (PSA) testing, is a contentious topic that received negative attention due to the low sensitivity and specificity of PSA to detect cli...
-
Article
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Mutations in the BRCA1 and BRCA2 tumour suppressor genes are associated with prostate cancer risk; however, optimal screening protocols for individuals with these mutations have been a subject of debate. Several ...
-
Article
Open AccessActive surveillance in renal transplant patients with prostate cancer: a multicentre analysis
Due to medical improvements leading to increased life expectancy after renal transplantation and widened eligibility criteria allowing older patients to be transplanted, incidence of (low-risk) prostate cancer...
-
Article
Open AccessFull functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy
The objective of the study was to test the impact of implementing standard full functional-length urethral sphincter (FFLU) and neurovascular bundle preservation (NVBP) with intraoperative frozen section techn...
-
Article
Open AccessHistopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs?
Prostate cancer (PCa) detection is usually achieved by PSA measurement and, if indicated, further diagnostics. The recent EAU guidelines recommend a first PSA test at the age of 50 years, if no family history ...
-
Article
Multimodale Therapie des Hochrisiko- und lokal fortgeschrittenen Prostatakarzinoms
Die Behandlung des Hochrisiko- und lokal fortgeschrittenen Prostatakarzinoms stellt eine Herausforderung im ärztlichen Alltag dar. Mit 20–40 % machen Patienten mit solch einem Tumorstadium aktuell einen Großte...
